Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup in Patients Suffering a URTI

Upper Respiratory Infections Clinical Trial

Official title:

An Open Label, In-use Study to Assess the Warming Sensation, Acceptability and Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup Given as a 30 ml Single Dose in Subjects Suffering From Symptoms of an Upper Respiratory Tract Infection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01586962
• Other study ID #: 147-A-301
• Status: Completed
• Phase: Phase 3
• First received: April 23, 2012
• Last updated: August 6, 2013
• Start date: May 2012
• Est. completion date: May 2012

Study information

• Verified date: April 2013
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

This is an open label, in-use study to assess the warming sensation, acceptability and local tolerability of paracetamol 500 mg + pseudoephedrine 30 mg syrup, given as a single dose in subjects suffering from symptoms of an upper respiratory tract infection. The purpose is to evaluate the acceptability concerning a warming sensation effect and its potential benefit in the target population.

The primary objective is to assess the warming sensation caused by the excipient IFF flavor 316 282, in a syrup containing paracetamol 500 mg + pseudoephedrine 30 mg per 30 ml syrup. The syrup contains (0.15% w/v) warming flavor.

The Secondary Objectives are to assess subject acceptability of the syrup and the safety and tolerability of the syrup. The study will be run in fifty-six (56) subjects suffering from symptoms of an upper respiratory tract infection (URTI) for 7 days or less, e.g. nasal congestion associated with colds and flu symptoms such as pain, headache and/or fever. Subjects must have one or more symptoms per category:

1. mild to moderate body pain, headache, fever or sore throat

2. nasal congestion (blocked nose) with or without rhinorrhea (runny nose) or sneezing Adolescents will be included in the study population

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: May 2012
• Est. primary completion date: May 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• Subject must have one or more symptoms per category (see also screening assessment of cold symptoms, section 6.1):

• mild to moderate body pain, headache, fever or sore throat

• nasal congestion (blocked nose) with or without rhinorrhea (runny nose) or sneezing

Exclusion Criteria:

1. Baseline sore throat pain of severe intensity, e.g. rated as 3 on a 4-point ordinal scale (0=not present, 1= mild, 2=moderate, 3=severe)

2. Baseline dry cough of severe intensity, e.g. rated as 3 on a 4-point ordinal scale (0=not present, 1= mild, 2=moderate, 3=severe)

3. Subject has a productive cough.

4. History of hypersensitivity to any of the study drugs and the listed excipients or to drugs of similar chemical classes

5. Subjects with allergic asthma.

6. Use of any inhaler, medicated confectionary, throat lozenges, throat pastilles, sprays, any products with demulcent properties such as chewing gums and boiled sweets or mints, in the 6 hours prior to dosing.

7. Use of any medication for sore throat containing a local anaesthetic within the 6 hours prior to dosing.

8. Use of paracetamol, any NSAID or any oral nasal decongestant within 6 hours prior to dosing.

9. Use of substances of abuse or antihistamines within 24 hours of dosing.

10. Drinking of tea, coffee or other caffeinated beverages 1 hour prior to dosing.

11. Suffering from hepatic or severe renal impairment, hypertension, hyperthyroidism, diabetes, heart disease or other acute or chronic medical condition that, in the opinion of the investigator, would put the subject at a higher risk or affect the conduct and/or the results of the study.

12. Use of any antidepressants, monoamine oxidase inhibitors or beta-blocking drugs in the 28 days prior to dosing

13. A history of alcohol abuse or subject admits to regular consumption of alcohol in excess of the recommended weekly limits of 21 units for females and 28 units for males.

14. Subject is a current smoker of =10 cigarettes per day (or reports equivalent smoking habits using other tobacco products).

15. Subject has smoked or chewed tobacco products within 12 hours of dosing.

16. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Infection
• Respiratory Tract Infections
• Upper Respiratory Infections

Intervention

Drug:
• IFF flavor 316 282, Paracetamol, Pseudoephedrine
Single dose syrup containing a warmingflavor IFF 316282 in a syrup containing Paracetamol and pseudoephedrine

Locations

Country	Name	City	State
Canada	Algorithme Pharma	Montreal	Quebec

Sponsors (2)

Lead Sponsor	Collaborator
Novartis	Novartis Consumer Health

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Warming Sensation Caused by the Excipient IFF Flavor 316 282, in a Syrup Containing Paracetamol 500 mg + Pseudoephedrine 30 mg Per 30 ml Syrup	Intensity of warming sensation felt by subjects between predose to 1 minute postdose where 0 = no warming sensation and 100 = strongest possible warming sensation	1 minute	No
Secondary	Subject Acceptability of the Syrup	How do you like the warming sensation you have experienced for this product?; Possible responses are : Like extremely Like very much Like moderately Like slightly Neither like nor dislike Dislike slightly Dislike moderately Dislike very much Dislike extremely	1 hour	No
Secondary	Safety and Tolerability of the Syrup	Number of participants with adverse events.	1 hour	No